KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Total Non-Current Liabilities: 2010-2024

Historic Total Non-Current Liabilities for Ionis Pharmaceuticals (IONS) over the last 10 years, with Dec 2024 value amounting to $2.4 billion.

  • Ionis Pharmaceuticals' Total Non-Current Liabilities rose 26.90% to $2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year increase of 26.90%. This contributed to the annual value of $2.4 billion for FY2024, which is 13.10% up from last year.
  • Ionis Pharmaceuticals' Total Non-Current Liabilities amounted to $2.4 billion in FY2024, which was up 13.10% from $2.1 billion recorded in FY2023.
  • Ionis Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $2.4 billion during FY2024, with a 5-year trough of $1.8 billion in FY2021.
  • In the last 2 years, Ionis Pharmaceuticals' Total Non-Current Liabilities had a median value of $2.2 billion in 2023 and averaged $2.2 billion.
  • Data for Ionis Pharmaceuticals' Total Non-Current Liabilities shows a peak YoY increased of 13.10% (in 2024) over the last 5 years.
  • Ionis Pharmaceuticals' Total Non-Current Liabilities (Yearly) stood at $1.8 billion in 2021, then reached $2.1 billion in 2023, then climbed by 13.10% to $2.4 billion in 2024.